Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi. The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, which generated a $40 million milestone payment under the terms of the collaboration. Study completion dates for both trials are projected in the first quarter of 2025.
- The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD.
- Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023 , which generated a $40 million milestone payment under the terms of the collaboration.
- Study completion dates for both trials are projected in the first quarter of 2025.
- “We are pleased to be working with Kymera to explore the potential of IRAK4 degradation to treat a variety of inflammatory conditions, including in our recently initiated Phase 2 AD and HS trials.”